A detailed history of China Universal Asset Management Co., Ltd. transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 29,989 shares of OCUL stock, worth $297,490. This represents 0.03% of its overall portfolio holdings.

Number of Shares
29,989
Previous 18,196 64.81%
Holding current value
$297,490
Previous $124,000 109.68%
% of portfolio
0.03%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$6.45 - $9.23 $76,064 - $108,849
11,793 Added 64.81%
29,989 $260,000
Q2 2024

Jul 19, 2024

SELL
$4.2 - $8.69 $12,612 - $26,096
-3,003 Reduced 14.17%
18,196 $124,000
Q1 2024

Apr 29, 2024

BUY
$3.85 - $10.93 $46,226 - $131,236
12,007 Added 130.62%
21,199 $193,000
Q4 2023

May 21, 2024

SELL
$2.08 - $4.52 $24,974 - $54,271
-12,007 Reduced 56.64%
9,192 $40,000
Q4 2023

Jan 23, 2024

BUY
$2.08 - $4.52 $14,876 - $32,327
7,152 Added 350.59%
9,192 $41,000
Q3 2023

May 21, 2024

BUY
$3.14 - $5.04 $3,215 - $5,160
1,024 Added 100.79%
2,040 $6,000
Q3 2023

Oct 30, 2023

BUY
$3.14 - $5.04 $3,215 - $5,160
1,024 Added 100.79%
2,040 $6,000
Q2 2023

May 21, 2024

SELL
$4.6 - $7.64 $124 - $206
-27 Reduced 2.59%
1,016 $5,000
Q2 2023

Jul 27, 2023

SELL
$4.6 - $7.64 $124 - $206
-27 Reduced 2.59%
1,016 $5,000
Q1 2023

May 21, 2024

BUY
$2.79 - $6.27 $728 - $1,636
261 Added 33.38%
1,043 $5,000
Q1 2023

Apr 27, 2023

BUY
$2.79 - $6.27 $728 - $1,636
261 Added 33.38%
1,043 $5,000
Q4 2022

May 21, 2024

SELL
$2.61 - $4.41 $53,288 - $90,038
-20,417 Reduced 96.31%
782 $2,000
Q4 2022

Jan 31, 2023

BUY
$2.61 - $4.41 $159 - $269
61 Added 8.46%
782 $2,000
Q3 2022

Oct 21, 2022

BUY
$4.09 - $6.5 $2,948 - $4,686
721 New
721 $3,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $764M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.